NDC 70114-441

CIMERLI

Ranibizumab-eqrn

CIMERLI is a Intravitreal Injection, Solution in the Human Prescription Drug category. It is labeled and distributed by Coherus Biosciences Inc. The primary component is Ranibizumab.

• Product ID: 70114-441_557e9461-76e9-4d5a-a165-b11af0979d39
• NDC: 70114-441
• Product Type: Human Prescription Drug
• Proprietary Name: CIMERLI
• Generic Name: Ranibizumab-eqrn
• Dosage Form: Injection, Solution
• Route of Administration: INTRAVITREAL
• Marketing Start Date: 2022-10-03
• Marketing Category: BLA /
• Application Number: BLA761165
• Labeler Name: Coherus BioSciences Inc
• Substance Name: RANIBIZUMAB
• Active Ingredient Strength: 1 mg/.05mL
• Pharm Classes: Vascular Endothelial Growth Factor Inhibitor [EPC], Vascular Endothelial Growth Factor Inhibitors [MoA]
• NDC Exclude Flag: N
• Listing Certified Through: 2023-12-31

Packaging

NDC 70114-441-01

1 VIAL, SINGLE-DOSE in 1 CARTON (70114-441-01) > .05 mL in 1 VIAL, SINGLE-DOSE

• Marketing Start Date: 2022-10-03
• NDC Exclude Flag: N
• Sample Package?: N

Drug Details

NDC Crossover Matching brand name "CIMERLI" or generic name "Ranibizumab-eqrn"

NDC	Brand Name	Generic Name
70114-440	CIMERLI	ranibizumab-eqrn
70114-441	CIMERLI	ranibizumab-eqrn